Physician profile
Kirit Bhatt
NPI 1245428663
$18,709.64
in general payments reported to CMS, 2019-2025
8 companies · $1,127 in 2025
The $1,127 reported for 2025 was more than what 75% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,041 · 2020: $234 · 2021: $23.43 · 2022: $378 · 2023: $16K · 2024: $156 · 2025: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $16K · Long Term Medical Supply Or Device Loan: $1,084 · Food and Beverage: $352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $15,595.93 |
| Long Term Medical Supply Or Device Loan | $1,084.35 |
| Food and Beverage | $352.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Health Care Systems INC. | $15,595.93 | 2023 | |
| Integra Lifesciences Corporation | $2,124.77 | 2019-2025 | Amnioexcel Plus, Amnioexcel, Integra |
| Smith+Nephew, INC. | $343.85 | 2020-2022 | |
| Allergan, INC. | $248.01 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $153.12 | 2023 | |
| Abbvie INC. | $113.91 | 2024 | |
| Innovation Technologies INC | $87.81 | 2020 | |
| Tela Bio, INC. | $42.24 | 2024 | Ovitex 2s |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirit Bhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.